Build Your Comparison

Side-by-side financial analysis
ACOG logo
ACOG
LLY logo
LLY
Try popular comparisons:

Stock Comparison

ACOG vs LLY

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ACOG
Alpha Cognition Inc. Common Stock

Financial - Conglomerates

Financial ServicesNASDAQ • CA
Market Cap$98M
5Y Perf.-4.8%
LLY
Eli Lilly and Company

Drug Manufacturers - General

HealthcareNYSE • US
Market Cap$1.07T
5Y Perf.+42.5%

ACOG vs LLY — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ACOG logoACOG
LLY logoLLY
IndustryFinancial - ConglomeratesDrug Manufacturers - General
Market Cap$98M$1.07T
Revenue (TTM)$11M$72.25B
Net Income (TTM)$-25M$25.27B
Gross Margin86.4%83.5%
Operating Margin-250.1%45.9%
Forward P/E30.9x
Total Debt$0.00$42.50B
Cash & Equiv.$66M$7.16B

ACOG vs LLYLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ACOG
LLY
StockNov 24Jun 26Return
Alpha Cognition Inc… (ACOG)10095.2-4.8%
Eli Lilly and Compa… (LLY)100142.5+42.5%

Price return only. Dividends and distributions are not included.

Quick Verdict: ACOG vs LLY

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: LLY leads in 6 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇LLY emerged as the overall leader. Track its performance:
ACOG
Alpha Cognition Inc. Common Stock
The Financial Play

In this particular matchup, ACOG is outpaced on most metrics by others in the set.

Best for: financial services exposure
LLY
Eli Lilly and Company
The Income Pick

LLY carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 11 yrs, beta 0.53, yield 0.5%
  • Rev growth 44.7%, EPS growth 96.0%, 3Y rev CAGR 31.7%
  • 14.8% 10Y total return vs ACOG's -11.3%
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthLLY logoLLY44.7% revenue growth vs ACOG's -116.5%
Quality / MarginsLLY logoLLY35.0% margin vs ACOG's -232.2%
Stability / SafetyLLY logoLLYBeta 0.53 vs ACOG's 1.29
DividendsLLY logoLLY0.5% yield; 11-year raise streak; the other pay no meaningful dividend
Momentum (1Y)LLY logoLLY+40.3% vs ACOG's -34.4%
Efficiency (ROA)LLY logoLLY22.7% ROA vs ACOG's -41.8%, ROIC 41.8% vs -32.4%

ACOG vs LLY — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
ACOGAlpha Cognition Inc. Common Stock
FY 2025
Service
100.0%$433,221
LLYEli Lilly and Company
FY 2025
Product
93.5%$61.0B
Collaboration and Other Revenue
6.5%$4.2B

ACOG vs LLY — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLLLYLAGGINGACOG

Income & Cash Flow (Last 12 Months)

LLY leads this category, winning 4 of 5 comparable metrics.

LLY is the larger business by revenue, generating $72.2B annually — 6674.1x ACOG's $11M. LLY is the more profitable business, keeping 35.0% of every revenue dollar as net income compared to ACOG's -2.3%.

MetricACOG logoACOGAlpha Cognition I…LLY logoLLYEli Lilly and Com…
RevenueTrailing 12 months$11M$72.2B
EBITDAEarnings before interest/tax-$27M$34.7B
Net IncomeAfter-tax profit-$25M$25.3B
Free Cash FlowCash after capex-$30M$13.6B
Gross MarginGross profit ÷ Revenue+86.4%+83.5%
Operating MarginEBIT ÷ Revenue-2.5%+45.9%
Net MarginNet income ÷ Revenue-2.3%+35.0%
FCF MarginFCF ÷ Revenue-2.8%+18.8%
Rev. Growth (YoY)Latest quarter vs prior year+55.5%
EPS Growth (YoY)Latest quarter vs prior year-146.2%+169.9%
LLY leads this category, winning 4 of 5 comparable metrics.

Valuation Metrics

ACOG leads this category, winning 3 of 3 comparable metrics.
MetricACOG logoACOGAlpha Cognition I…LLY logoLLYEli Lilly and Com…
Market CapShares × price$98M$1.07T
Enterprise ValueMkt cap + debt − cash$32M$1.11T
Trailing P/EPrice ÷ TTM EPS-5.38x49.37x
Forward P/EPrice ÷ next-FY EPS est.30.95x
PEG RatioP/E ÷ EPS growth rate1.71x
EV / EBITDAEnterprise value multiple35.38x
Price / SalesMarket cap ÷ Revenue9.57x16.42x
Price / BookPrice ÷ Book value/share1.78x38.34x
Price / FCFMarket cap ÷ FCF119.31x
ACOG leads this category, winning 3 of 3 comparable metrics.

Profitability & Efficiency

LLY leads this category, winning 5 of 7 comparable metrics.

LLY delivers a 101.2% return on equity — every $100 of shareholder capital generates $101 in annual profit, vs $-54 for ACOG. On the Piotroski fundamental quality scale (0–9), LLY scores 8/9 vs ACOG's 4/9, reflecting strong financial health.

MetricACOG logoACOGAlpha Cognition I…LLY logoLLYEli Lilly and Com…
ROE (TTM)Return on equity-54.1%+101.2%
ROA (TTM)Return on assets-41.8%+22.7%
ROICReturn on invested capital-32.4%+41.8%
ROCEReturn on capital employed-38.4%+46.6%
Piotroski ScoreFundamental quality 0–948
Debt / EquityFinancial leverage1.60x
Net DebtTotal debt minus cash-$66M$35.3B
Cash & Equiv.Liquid assets$66M$7.2B
Total DebtShort + long-term debt$0$42.5B
Interest CoverageEBIT ÷ Interest expense35.68x
LLY leads this category, winning 5 of 7 comparable metrics.

Total Returns (Dividends Reinvested)

LLY leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in LLY five years ago would be worth $51,207 today (with dividends reinvested), compared to $8,873 for ACOG. Over the past 12 months, LLY leads with a +40.3% total return vs ACOG's -34.4%. The 3-year compound annual growth rate (CAGR) favors LLY at 37.2% vs ACOG's -3.9% — a key indicator of consistent wealth creation.

MetricACOG logoACOGAlpha Cognition I…LLY logoLLYEli Lilly and Com…
YTD ReturnYear-to-date-3.1%+5.2%
1-Year ReturnPast 12 months-34.4%+40.3%
3-Year ReturnCumulative with dividends-11.3%+158.2%
5-Year ReturnCumulative with dividends-11.3%+412.1%
10-Year ReturnCumulative with dividends-11.3%+1484.6%
CAGR (3Y)Annualised 3-year return-3.9%+37.2%
LLY leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

LLY leads this category, winning 2 of 2 comparable metrics.

LLY is the less volatile stock with a 0.53 beta — it tends to amplify market swings less than ACOG's 1.29 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LLY currently trades 95.8% from its 52-week high vs ACOG's 54.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricACOG logoACOGAlpha Cognition I…LLY logoLLYEli Lilly and Com…
Beta (5Y)Sensitivity to S&P 5001.29x0.53x
52-Week HighHighest price in past year$11.54$1182.73
52-Week LowLowest price in past year$4.50$623.78
% of 52W HighCurrent price vs 52-week peak+54.6%+95.8%
RSI (14)Momentum oscillator 0–10050.970.0
Avg Volume (50D)Average daily shares traded42K2.6M
LLY leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates ACOG as "Buy" and LLY as "Buy". Consensus price targets imply 122.2% upside for ACOG (target: $14) vs 12.0% for LLY (target: $1269). LLY is the only dividend payer here at 0.53% yield — a key consideration for income-focused portfolios.

MetricACOG logoACOGAlpha Cognition I…LLY logoLLYEli Lilly and Com…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$14.00$1268.94
# AnalystsCovering analysts145
Dividend YieldAnnual dividend ÷ price+0.5%
Dividend StreakConsecutive years of raises11
Dividend / ShareAnnual DPS$6.00
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.4%
Insufficient data to determine a leader in this category.
Key Takeaway

LLY leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ACOG leads in 1 (Valuation Metrics).

Best OverallEli Lilly and Company (LLY)Leads 4 of 6 categories
Loading custom metrics...

ACOG vs LLY: Frequently Asked Questions

9 questions · data-driven answers · updated daily

01

Is ACOG or LLY a better buy right now?

Eli Lilly and Company (LLY) offers the better valuation at 49.

4x trailing P/E (30. 9x forward), making it the more compelling value choice. Analysts rate Alpha Cognition Inc. Common Stock (ACOG) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — ACOG or LLY?

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +412.

1%, compared to -11. 3% for Alpha Cognition Inc. Common Stock (ACOG). Over 10 years, the gap is even starker: LLY returned +1485% versus ACOG's -11. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — ACOG or LLY?

By beta (market sensitivity over 5 years), Eli Lilly and Company (LLY) is the lower-risk stock at 0.

53β versus Alpha Cognition Inc. Common Stock's 1. 29β — meaning ACOG is approximately 144% more volatile than LLY relative to the S&P 500.

04

Which is growing faster — ACOG or LLY?

On earnings-per-share growth, the picture is similar: Eli Lilly and Company grew EPS 96.

0% year-over-year, compared to 42. 1% for Alpha Cognition Inc. Common Stock. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — ACOG or LLY?

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus -202. 2% for Alpha Cognition Inc. Common Stock — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -221. 7% for ACOG. At the gross margin level — before operating expenses — LLY leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is ACOG or LLY more undervalued right now?

Analyst consensus price targets imply the most upside for ACOG: 122.

2% to $14. 00.

07

Which pays a better dividend — ACOG or LLY?

In this comparison, LLY (0.

5% yield) pays a dividend. ACOG does not pay a meaningful dividend and should not be held primarily for income.

08

Is ACOG or LLY better for a retirement portfolio?

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

53), 0. 5% yield, +1485% 10Y return). Both have compounded well over 10 years (LLY: +1485%, ACOG: -11. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between ACOG and LLY?

These companies operate in different sectors (ACOG (Financial Services) and LLY (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ACOG is a small-cap quality compounder stock; LLY is a mega-cap high-growth stock. LLY pays a dividend while ACOG does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.